- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.10. | MapLight illuminates $262M IPO plans to fund Cobenfy competitor | ||
| 07.10. | AstraZeneca's $1.3B bet yields second phase 3 blood pressure win, bolstering differentiation case | ||
| 07.10. | How do you get pharmaceutical treatments where they're needed most? | ||
| 06.10. | TCG Crossover hauls in $1.3B for third investment fund in four years | ||
| 06.10. | AstraZeneca, Algen Biotechnologies pen $555M AI pact for immunology targets | ||
| 06.10. | Skye's shares crater as CB1 blocker fails to reduce weight in phase 2 obesity study | ||
| 06.10. | Ignota buys Kronos' pipeline, igniting 2nd chance salvo to rescue shelved programs | ||
| 06.10. | AbbVie flags $2.7B R&D hit to brace investors for lower full-year profit | ||
| 03.10. | Q3 biopharma layoffs hold steady, setting 2025 up to break last year's high | ||
| 03.10. | Leader of NIH's National Institute of Allergy and Infectious Diseases fired in alleged whistleblower retaliation | ||
| 03.10. | 4 reasons why life sciences still fail women at the top, despite a female-majority workforce: report | ||
| 03.10. | Rocket aborts mission to get gene therapy approved by FDA for rare bone marrow disorder | ||
| 02.10. | After courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks | ||
| 02.10. | Singapore drug discovery platform heads to Nasdaq via SPAC deal | ||
| 02.10. | Bolt halves workforce (again) to find cash to fund immunotherapy readout | ||
| 01.10. | Takeda taps out of cell therapy arena as part of strategic shift | ||
| 01.10. | FDA snubs Cyprium-Sentynl drug for rare pediatric disease due to manufacturing issues | ||
| 01.10. | Amid funding cuts, White House pledges $100M to pediatric cancer data initiative | ||
| 01.10. | Irish biotech launches with $21M to shuttle RNAi meds to brain | ||
| 01.10. | BMS and Takeda dive into AI data pool, joining peers in collaborative push to unfold the future | ||
| 01.10. | Kyorin pens $105M pact for Japan rights to Hinge's preclinical lupus drug | ||
| 30.09. | Novo dumps cell therapy partner Heartseed, calling off $598M collab amid restructuring | ||
| 30.09. | Barinthus Bio joins forces with metabolic disease biotech in reverse merger | ||
| 30.09. | AnaptysBio plans to split biotech and Jemperli royalties into separate businesses | ||
| 30.09. | Opus sets sights on FDA talks after posting pediatric gene therapy data |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .